RLMD

$0.00

(

0.00%

) Quote details
Add to Watchlist Run Backtest
stock

Relmada Therapeutics Inc

NASDAQ | RLMD

2.00

USD

$0.00

(

0.00%

)

At Close (As of Oct 16, 2025)

$68.71M

Market Cap

-

P/E Ratio

-2.2

EPS

$3.98

52 Week High

$0.24

52 Week Low

HEALTHCARE

Sector

RLMD Chart

Recent Chart
Price Action

RLMD Technicals

Tags:

RLMD Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -
Total Revenue $0
Cost Of Revenue -
Costof Goods And Services Sold -
Operating Income -$84M
Selling General And Administrative $38M
Research And Development $46M
Operating Expenses $84M
Investment Income Net -
Net Interest Income $3.5M
Interest Income $3.5M
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $84M
Income Before Tax -$80M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$80M
Comprehensive Income Net Of Tax -
Ebit -$164M
Ebitda -$80M
Net Income -$80M

Revenue & Profitability

Earnings Performance

RLMD Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $46M
Total Current Assets $46M
Cash And Cash Equivalents At Carrying Value $3.9M
Cash And Short Term Investments $3.9M
Inventory -
Current Net Receivables -
Total Non Current Assets $22K
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets -
Intangible Assets Excluding Goodwill -
Goodwill -
Investments -
Long Term Investments -
Short Term Investments $41M
Other Current Assets $886K
Other Non Current Assets -
Total Liabilities $10M
Total Current Liabilities $10M
Current Accounts Payable $4.1M
Deferred Revenue -
Current Debt -
Short Term Debt -
Total Non Current Liabilities $4.5K
Capital Lease Obligations -
Long Term Debt -
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total -
Other Current Liabilities $6.2M
Other Non Current Liabilities -
Total Shareholder Equity $36M
Treasury Stock -
Retained Earnings -$641M
Common Stock $30K
Common Stock Shares Outstanding $30M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$52M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization -
Capital Expenditures $0
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment $52M
Cashflow From Financing -$40K
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$80M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -
Total Revenue $0
Cost Of Revenue -
Costof Goods And Services Sold -
Operating Income -$84M
Selling General And Administrative $38M
Research And Development $46M
Operating Expenses $84M
Investment Income Net -
Net Interest Income $3.5M
Interest Income $3.5M
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $84M
Income Before Tax -$80M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$80M
Comprehensive Income Net Of Tax -
Ebit -$164M
Ebitda -$80M
Net Income -$80M

RLMD News

RLMD Profile

Relmada Therapeutics Inc Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

Relmada Therapeutics, Inc. is a clinical-stage biotechnology company based in New York, committed to advancing innovative therapies for central nervous system (CNS) disorders and associated conditions. The company is focused on developing a robust pipeline of candidates aimed at addressing critical unmet medical needs in pain management and psychiatric disorders, utilizing cutting-edge research and technology. By prioritizing patient outcomes, Relmada is strategically positioned to become a significant contributor in the rapidly evolving CNS therapeutics market, potentially offering valuable solutions for patients and healthcare providers alike.

YYAI
-10.40%
$0.13
VHAI
-20.00%
$0.00
VIVK
-1.72%
$0.28
BURU
-17.95%
$0.33
RXRX
-6.33%
$6.36
EPWK
+26.46%
$0.09
IVF
+85.67%
$1.40
BITF
-18.39%
$5.28
CGBS
-39.47%
$0.03
COOT
+173.57%
$2.64
YDKG
-49.73%
$0.09
NVDA
+1.10%
$181.81
PLUG
-8.70%
$3.51
ADAP
+6.02%
$0.19
BYND
-22.39%
$0.52
NVTS
+3.10%
$15.63
RGTI
-14.85%
$47.97
DNN
-2.83%
$3.08
LAES
-2.09%
$7.49
NIO
-1.09%
$6.74
MIRA
+36.36%
$1.80
F
-0.12%
$11.74
AMD
+9.40%
$238.60
SCNX
-17.63%
$0.58
BBD
+1.71%
$3.25
INTC
+4.26%
$37.15
KVUE
-13.22%
$14.11
ACHR
-8.90%
$11.87
TLRY
-8.33%
$1.54
HPE
-10.06%
$22.52
TSLA
-1.47%
$428.75
IONZ
+19.44%
$3.44
ONDS
-13.77%
$8.19
DFLI
-32.48%
$1.33
SOFI
+0.57%
$28.03
AXDX
-61.36%
$0.03
ETHD
+6.47%
$3.78
RIG
-2.56%
$3.22
CAN
-14.28%
$1.68
MARA
-11.27%
$20.26
GDXD
-10.20%
$0.60
AMC
-2.30%
$2.75
BTBT
-9.11%
$3.69
GNPX
-43.39%
$0.47
QBTS
-9.62%
$40.47
BTG
+3.96%
$5.89
FEMY
+33.89%
$0.73
QS
-13.41%
$15.45
VSEE
-13.85%
$0.51
RR
-7.95%
$5.67
GPUS
-6.14%
$0.36
AAL
+2.54%
$12.50
ABAT
-21.00%
$8.94
NAK
-4.34%
$2.64
SNAP
-1.83%
$7.76
QUBT
-11.72%
$18.73
QSI
-3.42%
$2.54
CIFR
-10.98%
$18.72
WOK
+1.55%
$0.05
CRML
-14.52%
$19.42
RF
-5.98%
$23.26
RGTZ
+30.51%
$11.35
IREN
-9.04%
$61.83
ASST
-6.24%
$0.90
PFE
-0.65%
$24.23
MASK
+17.35%
$0.57
UUUU
-12.80%
$21.79
KEY
-5.35%
$16.78
HBAN
-5.00%
$15.39
AMZN
-0.51%
$214.47
MU
+5.51%
$202.53
WTO
-88.87%
$0.13
SOUN
-2.99%
$20.76
JBLU
-3.63%
$4.76
CLSK
-13.92%
$19.97
SMR
-10.87%
$47.62
T
+0.46%
$26.19
RMBL
+60.50%
$3.21
GRAB
-3.54%
$5.71
AAPL
-0.75%
$247.45
NOK
+0.35%
$5.67
ADD
-25.47%
$0.05
SOND
+79.34%
$1.65
PLTR
-0.06%
$179.62
AUUD
+0.97%
$2.06
SLNH
-2.33%
$4.19
WULF
-9.53%
$13.99
JOBY
-8.66%
$16.07
BAC
-4.03%
$50.17
IONQ
-9.33%
$65.65
APLD
-1.69%
$37.11
TOVX
-48.34%
$0.43
NEHC
+9.12%
$3.35
CLF
-0.07%
$13.95
SRM
+53.27%
$10.30
SATL
-29.71%
$2.91
BMNR
-4.90%
$51.16
KDLY
+1.29%
$0.79
HIMS
-6.07%
$58.94
ORCL
+3.08%
$313.00
YYAI
-10.40%
$0.13
VHAI
-20.00%
$0.00
VIVK
-1.72%
$0.28
BURU
-17.95%
$0.33
RXRX
-6.33%
$6.36
EPWK
+26.46%
$0.09
IVF
+85.67%
$1.40
BITF
-18.39%
$5.28
CGBS
-39.47%
$0.03
COOT
+173.57%
$2.64
YDKG
-49.73%
$0.09
NVDA
+1.10%
$181.81
PLUG
-8.70%
$3.51
ADAP
+6.02%
$0.19
BYND
-22.39%
$0.52
NVTS
+3.10%
$15.63
RGTI
-14.85%
$47.97
DNN
-2.83%
$3.08
LAES
-2.09%
$7.49
NIO
-1.09%
$6.74
MIRA
+36.36%
$1.80
F
-0.12%
$11.74
AMD
+9.40%
$238.60
SCNX
-17.63%
$0.58
BBD
+1.71%
$3.25
INTC
+4.26%
$37.15
KVUE
-13.22%
$14.11
ACHR
-8.90%
$11.87
TLRY
-8.33%
$1.54
HPE
-10.06%
$22.52
TSLA
-1.47%
$428.75
IONZ
+19.44%
$3.44
ONDS
-13.77%
$8.19
DFLI
-32.48%
$1.33
SOFI
+0.57%
$28.03
AXDX
-61.36%
$0.03
ETHD
+6.47%
$3.78
RIG
-2.56%
$3.22
CAN
-14.28%
$1.68
MARA
-11.27%
$20.26
GDXD
-10.20%
$0.60
AMC
-2.30%
$2.75
BTBT
-9.11%
$3.69
GNPX
-43.39%
$0.47
QBTS
-9.62%
$40.47
BTG
+3.96%
$5.89
FEMY
+33.89%
$0.73
QS
-13.41%
$15.45
VSEE
-13.85%
$0.51
RR
-7.95%
$5.67
GPUS
-6.14%
$0.36
AAL
+2.54%
$12.50
ABAT
-21.00%
$8.94
NAK
-4.34%
$2.64
SNAP
-1.83%
$7.76
QUBT
-11.72%
$18.73
QSI
-3.42%
$2.54
CIFR
-10.98%
$18.72
WOK
+1.55%
$0.05
CRML
-14.52%
$19.42
RF
-5.98%
$23.26
RGTZ
+30.51%
$11.35
IREN
-9.04%
$61.83
ASST
-6.24%
$0.90
PFE
-0.65%
$24.23
MASK
+17.35%
$0.57
UUUU
-12.80%
$21.79
KEY
-5.35%
$16.78
HBAN
-5.00%
$15.39
AMZN
-0.51%
$214.47
MU
+5.51%
$202.53
WTO
-88.87%
$0.13
SOUN
-2.99%
$20.76
JBLU
-3.63%
$4.76
CLSK
-13.92%
$19.97
SMR
-10.87%
$47.62
T
+0.46%
$26.19
RMBL
+60.50%
$3.21
GRAB
-3.54%
$5.71
AAPL
-0.75%
$247.45
NOK
+0.35%
$5.67
ADD
-25.47%
$0.05
SOND
+79.34%
$1.65
PLTR
-0.06%
$179.62
AUUD
+0.97%
$2.06
SLNH
-2.33%
$4.19
WULF
-9.53%
$13.99
JOBY
-8.66%
$16.07
BAC
-4.03%
$50.17
IONQ
-9.33%
$65.65
APLD
-1.69%
$37.11
TOVX
-48.34%
$0.43
NEHC
+9.12%
$3.35
CLF
-0.07%
$13.95
SRM
+53.27%
$10.30
SATL
-29.71%
$2.91
BMNR
-4.90%
$51.16
KDLY
+1.29%
$0.79
HIMS
-6.07%
$58.94
ORCL
+3.08%
$313.00
2025 © AfterPullback LTD

Charts powered by TradingView

Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.